Breast Cancer Guideline Updates 2024 : Episode 5
Opinion
Video
NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib
William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importance of monitoring treatment response.
- Abemaciclib has been integrated into the NCCN Guidelines for certain patients with high-risk early-stage disease. What data is needed for ribociclib to find a similar position in the guidelines?
- What are the guideline recommendations for monitoring for response to systemic treatment in breast cancer? What outcomes are most important when monitoring response to treatment?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
